← Back to Clinical Trials
Recruiting NCT05929898

NCT05929898 MRI Neurofeedback and Brain Circuits Related to Motivation in Healthy Participants

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05929898
Status Recruiting
Phase
Sponsor Duke University
Condition Motivation
Study Type INTERVENTIONAL
Enrollment 190 participants
Start Date 2023-07-30
Primary Completion 2026-09-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 190 participants in total. It began in 2023-07-30 with a primary completion date of 2026-09-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research study is to understand how healthy individuals self-regulate motivation by observing brain activity using magnetic resonance imaging (MRI).

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 45 years * Male or female * Right-handed * In good general health * Women of childbearing capacity: use of effective method of birth control Exclusion Criteria: * Current or diagnosis within past six months of an DSM-V Axis I or Axis II disorder (self-reported) * CES-D score of 20 or higher (indicating significant current depression symptoms) * Current or past six month use of prescription medications indicated for psychiatric conditions (e.g.,depression, anxiety) * Current serious medical illness (self-reported) * Head injury resulting in loss of consciousness * For participants age \> 59 years, a total scaled score \< 8 on the Dementia Rating Scale-2. * A clinically-defined neurological disorder including, but not limited to: * Any condition likely to be associated with increased intracranial pressure * Space occupying brain lesion * History of stroke * Transient ischemic attack within two years * Cerebral aneurysm * Dementia * Mini Mental Status Exam (MMSE) score of \<24 * Parkinson's disease * Huntington's disease * Multiple sclerosis * Presence of cochlear implants or other implanted electronic devices or non-removable metal (e.g., non-removable piercing, IUD) * History of an eye injury involving metal. Participants who worked with metal may be allowed to participate on a case-by-case basis with prior written approval from BIAC. * Claustrophobia or unwillingness to tolerate the confinement associated with being in the MRI scanner. * Weight of more than 250 pounds

Contact & Investigator

Central Contact

Laura Yost

✉ laura.yost@duke.edu

📞 919-681-4601

Principal Investigator

R. Alison Adock, MD, PhD

PRINCIPAL INVESTIGATOR

Duke University

Frequently Asked Questions

Who can join the NCT05929898 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Motivation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05929898 currently recruiting?

Yes, NCT05929898 is actively recruiting participants. Contact the research team at laura.yost@duke.edu for enrollment information.

Where is the NCT05929898 trial being conducted?

This trial is being conducted at Durham, United States.

Who is sponsoring the NCT05929898 clinical trial?

NCT05929898 is sponsored by Duke University. The principal investigator is R. Alison Adock, MD, PhD at Duke University. The trial plans to enroll 190 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology